DFDA

Ruxolitinib Cream (Opzelura)

Treatment for Vitiligo

Typical Dosage: Apply thin layer twice daily to affected areas up to 20% BSA

Effectiveness
75%
Safety Score
60%
Clinical Trials
1
Participants
1.2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Apply thin layer twice daily to affected areas up to 20% BSA
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$23,000
Monitoring:$300
Side Effect Mgmt:$100
Total Annual:$23,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$119,726/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$58,500
Cost per Remission
$234,000
Ruxolitinib Cream (Opzelura) Outcomes

for Vitiligo

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+40%
Remission Rate
+10%
Common Side Effects
Acne
+20%
Application site pruritus
+10%
Nasopharyngitis
+5%

Sources:

fda.gov
incyte.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
1 completed trial for Ruxolitinib Cream (Opzelura) in Vitiligo

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

NCT05750823COMPLETEDPHASE2
View Study
49 participants
INTERVENTIONAL
Fremont, United States +12 more
Started: Apr 11, 2023